RxDoctor Payments Data

Robert Learch, DO

Internal Medicine · Paducah, KYNPI 1174882658

Payments from drug & device makers

$2,731in general payments, 2019–2025

Across 187 payments — averaging $14.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$579
  • Novo Nordisk$563
  • Pfizer$365
  • AstraZeneca$307
  • Lilly USA, LLC$201
  • AbbVie$166
  • plus $550 from 10 others

What the payments were for

  • Food & beverage$2,71799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,731 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$94,701
Medicare patients
277
Services billed
1,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$139,889
JardianceEmpagliflozin95$91,550
FarxigaDapagliflozin Propanediol79$83,187
EliquisApixaban68$79,823
Tresiba Flextouch U-200Insulin Degludec43$48,029
RybelsusSemaglutide17$28,124
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$20,828
JanuviaSitagliptin Phosphate12$15,422
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$14,031
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,746
Breo ElliptaFluticasone/Vilanterol18$8,586
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$6,130
Insulin Lispro Kwikpen U-100Insulin Lispro23$5,750
Novolog FlexpenInsulin Aspart16$5,347
Atorvastatin Calcium506$3,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$563$168,013118 claims
AstraZenecaFarxiga, Breztri Aerosphere$307$104,015104 claims
Boehringer IngelheimJardiance$579$91,55095 claims
PfizerEliquis$365$79,82368 claims
GSKTrelegy Ellipta, Breo Ellipta$29$18,33230 claims
MerckJanuvia$48$15,42212 claims
AbbVieSynthroid$166$2,03925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →